Canopy Growth Reports Fourth Quarter and Fiscal Year 2024 Financial Results; Q4 FY2024 Net Revenue increased 7% year-over-year, or 16% excluding divested businesses
Storz & Bickel(®) delivered its best Q4 revenue quarter, with net revenue increasing 43% as compared to Q4 2023
Canada medical cannabis net revenue increased 16% in Q4 FY2024 and 10% in FY2024 year-over-year
Canada cannabis Cost of Goods Sold decreased by 54% in FY2024 versus FY2023
Following recent balance sheet actions, the Company has no material debt obligation due until March 2026(1)
SMITHS FALLS, ON, May 30, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy", "Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis, today announced its financial results for the fourth quarter and fiscal year ended March 31, 2024 and the filing of an annual report on Form 10-K, including the audited consolidated financial statements for the fiscal year ended March 31, 2024 and the unqualified report thereon of the Company's independent registered public accounting firm. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.
-- Storz & Bickel(®) net revenue in Q4 FY2024 increased 43% as compared to
Q4 FY2023 driven by strong sales of the new Venty portable vaporizer.
-- Canada cannabis net revenue in Q4 FY2024 increased 4% as compared to Q4
FY2023 led by a 16% increase in the Canada medical cannabis business.
-- Total Cost of Goods Sold ("COGS") decreased by 45% in FY2024 and Canada
cannabis COGS decreased by 54% year-over-year, driven by the cost
reduction actions.
-- Consolidated Gross Margins increased to 27%, an improvement of 4,600
basis points year-over-year in FY2024, with Canada cannabis,
International markets cannabis and Storz & Bickel all posting higher
Gross Margins year-over-year.
-- Operating loss from continuing operations of $229 MM in FY2024. Adjusted
EBITDA loss was $59 MM in FY2024, representing an improvement of 72%
year-over-year, driven primarily by revenue growth and successful cost
reduction actions taken to date.
-- Cash, cash equivalents, and short-term investments of $203 MM at March
31, 2024. Benefiting from balance sheet strengthening actions completed
subsequent to the end of FY2024, the Company has no material debt due
until March 2026.
"In Fiscal 2024 we fortified Canopy's foundation for future growth. With a resolute focus on cannabis, we have momentum and are poised to seize the opportunity presented by continued regulatory developments in Germany and the United States. Entering FY2025, Canopy has growing businesses in all of the world's most attractive cannabis markets, a leading portfolio of high-impact brands, and a rapidly developing U.S. ecosystem.''
David Klein, Chief Executive Officer
"We have made remarkable progress and delivered dramatic reductions in expenses, cash burn, and debt over the past year. These efforts have significantly enhanced our financial stability and moved us toward achieving positive Consolidated Adjusted EBTIDA. With no material debt maturing until 2026, Canopy is equipped to capitalize on growth opportunities and enhance shareholder value."
Judy Hong, Chief Financial Officer
(in millions of Canadian Net Revenue Gross margin Adjusted Net loss
from Adjusted Free cash
EBITDA
4
dollars, unaudited) percentage gross margin continuing (3) flow
percentage
(2) operations
Reported $72.8 21 % 21 % $(94.7) $(15.1) $(22.7)
vs. Q4 FY2023 7 % 11,500 bps 1,000 bps 84 % 63 % 77 %
(in millions of Canadian Net Revenue Gross margin Adjusted Net loss
from Adjusted Free cash
dollars, unaudited) percentage gross margin continuing EBITDA flow
percentage5 operations
Reported $297.1 27 % 27 % $(483.7) $(58.9) $(231.9)
vs. FY2023 (11 %) 4,600 bps 2,200 bps 84 % 72 % 43 %
-- Storz & Bickel(®) net revenue in Q4 FY2024 increased 43% as compared to
Q4 FY2023 to $22 MM driven by strong sales of the new Venty portable
vaporizer. Storz & Bickel Gross Margins improved to 41% in Q4 FY2024
driven primarily by a positive shift in product mix.
-- Canada medical cannabis delivered its 5th consecutive quarter of revenue
growth in Q4 FY2024 with revenue increasing 16% as compared to Q4 FY2023
benefiting from customer mix and larger product assortment in the
Spectrum Therapeutics online store. Canada cannabis segment revenue in
Q4 FY2024 increased 4% as compared to Q4 FY2023 to $37 MM driven by
growth in the Canadian medical cannabis business.
-- International markets cannabis net revenue in Q4 FY2024 increased 32% as
compared to Q4 FY2023 to $12 MM driven by growth in Germany and Poland
as well as the timing of revenue from the US CBD business which is
non-recurring. International markets cannabis Gross Margins improved by
5000 bps to 54% in Q4 FY2024 driven primarily by change in geographic
mix and impact from non-recurring revenue from the US CBD business.
-- Consolidated Gross Margins in Q4 FY2024 improved to 21% due to cost
reduction activities, as well as lower excess and obsolete inventory
charges in Canada cannabis. Q4 FY2024 Canada Gross Margins, however,
were negatively impacted by lower cultivation yields partly due to
seasonality, and an associated reduction in manufacturing utilization,
which are expected to improve in FY2025.
-- Selling, general & administrative ("SG&A") expenses in Q4 FY2024
declined 23% as compared to Q4 FY2023 primarily due to cost reduction
programs undertaken to date.
-- Cash outflow from operations improved 77% in Q4 FY2024 as compared to Q4
FY2023 driven by cost reduction programs and reduction in interest
payments.
-- Operating loss from continuing operations of $107 MM in Q4 FY2024,
representing an improvement of 80% as compared to Q4 FY2023. Adjusted
EBITDA loss was $15 MM in Q4 FY2024, representing a 63% improvement as
compared to Q4 FY2023.
-- Canada cannabis segment Gross Margins improved to 16% in FY2024 driven
by lower excess and obsolete inventory charges and lower operating
costs.
-- SG&A expenses declined by 33% compared to FY2023 primarily driven by
cost reductions actions executed in the first half of FY2024.
-- When adjusted for the sale of the Canadian retail business divested in
Q3 FY2023, Canada cannabis segment revenue increased by 2%
year-over-year to $154 MM in FY2024 driven primarily by growth in Canada
medical cannabis net revenue.
-- Canada medical cannabis net revenue increased 10% year-over-year to $61
MM in FY2024 driven by customer mix and a larger assortment of products
in the Spectrum Therapeautics online store.
-- International markets cannabis FY2024 net revenue increased 6%
year-over-year to $41 MM primarily attributable to growth in Australia.
International markets cannabis Gross Margins in FY2024 improved to 40%
primarily due to a positive shift in geographic mix.
Focus on innovation and increased distribution is driving growth in the Canadian cannabis market
-- Larger assortment of higher margin cannabis products on Spectrum
Therapeutic online store is contributing to growth in Canada medical
sales.
-- In Q4 FY2024, the Company launched new SKUs including new Tweed Lemon
Meringue Pie flower in large format 28g packs, and 7ACRES Jack Haze
Pre-rolled Joints ("PRJ") in a 0.5g x 14 large pack. Exclusive for
medical cannabis customers in Canada, extended the Spectrum Reserve
collection with Alien Breath and (GG#4 x Mendo Breath) PRJ in a 0.5g x
10 large pack.
-- The Company added over 2,300 points of distribution ("PODs") in the
Canadian adult-use market in Q4 FY2024 including 915 PODs for Tweed
flower, over 700 PODs for PRJ and over 650 PODs for Deep Space
beverages.
Multiple drivers of growth in International Markets medical cannabis
-- Benefiting from increasing supply of high-quality cannabis from Canada,
the Company obtained the top 4 market share in the German medical
cannabis market in FY2024(6).
-- Proven Canadian flower strains including Tweed Kush Mintz and Tweed
Tiger Cake, launched in Q3 FY2024, accounted for over 25% of net revenue
in Q4 FY2024.
Continued demand for new Venty vaporizer driving strong growth in Storz & Bickel net revenue
-- Significant growth in Storz & Bickel Q4 FY2024 net revenue driven in
part by continuing strong demand for the new Venty portable vaporizer.
-- Strong distributor and retailer load-in of all Storz & Bickel devices in
Q4 FY2024 experienced in advance of 4/20 events and sales promotions.
Canopy USA strategy advancing rapidly to seize U.S. opportunity
-- Subsequent to quarter end, shareholders of the Company overwhelmingly
approved the creation of a new class of non-voting and non-participating
exchangeable shares in the capital of the Company ("Exchangeable
Shares") at the special meeting of shareholders held on April 12, 2024.
-- Subsequent to quarter end, on April 18, 2024, Canopy Growth announced
that Constellation Brands Inc. converted its Common Shares to
Exchangeable Shares of the Company.
-- Subsequent to quarter end, on May 6, 2024, Canopy USA initiated the
acquisitions of Mountain High Products, LLC, Wana Wellness, LLC and The
Cima Group, LLC (collectively, "Wana") and Lemurian, Inc. ("Jetty").
These acquisitions are expected to close in the first half of FY2025.
Revenue by Channel
(in millions of Canadian dollars, unaudited) Q4 FY2024 Q4 FY2023 Vs. FY2024 FY2023 Vs. FY2023
Q4 FY2023
Canada cannabis
Canadian adult-use cannabis
Business-to-business8 $20.8 $21.6 (4 %) $92.4 $95.0 (3 %)
Business-to-consumer
$-
$- 0 %
$- $36.3 (100 %)
$20.8 $21.6 (4 %) $92.4 $131.3 (30 %)
Canada medical cannabis9 $16.3 $14.1 16 % $61.3 $55.8 10 %
$37.1 $35.7 4 % $153.7 $187.1 (18 %)
International markets cannabis10 $11.6 $8.8 32 % $41.3 $39.0 6 %
Storz & Bickel $22.2 $15.5 43 % $70.7 $64.8 9 %
This Works
$- $5.4 (100 %) $21.2 $26.0 (18 %)
Other $1.9 $2.8 (32 %) $10.2 $16.4 (38 %)
Net revenue $72.8 $68.2 7 % $297.1 $333.3 (11 %)
The Q4 FY2024, Q4 FY2023, FY2024 and FY2023 financial results presented in this press release have been prepared in accordance with U.S. GAAP.
_____________________
(1) Considering debt-related transactions completed subsequent to the end of FY2024
(2) Adjusted gross margin is a non-GAAP measure, and for Q4 FY2024 excludes $(0.3) million of restructuring cost reversals recorded in COGS (Q4 FY2023 - excludes $71.7 million of restructuring costs recorded in COGS). See "Non-GAAP Measures" and Schedule 4 for a reconciliation of net revenue to adjusted gross margin.
(3) Adjusted EBITDA is a non-GAAP measure. See "Non-GAAP Measures" and Schedule 5 for a reconciliation of net loss from continuing operations to adjusted EBITDA.
4 Free cash flow is a non-GAAP measure. See "Non-GAAP Measures" and Schedule 6 for a reconciliation of net cash used in operating activities - continuing operations to free cash flow - continuing operations.
5 Adjusted gross margin is a non-GAAP measure, and for FY2024 excludes $(1.0) million of restructuring cost reversals recorded in cost of goods sold (FY2023 - excludes $81.8 million of restructuring costs recorded in COGS). See "Non-GAAP Measures" and Schedule 4 for a reconciliation of net revenue to adjusted gross
margin.
6 Source: Insight Health Greenline ODV National Database
7 In Q4 FY2024, we are reporting our financial results for the following four reportable segments: (i) Canada cannabis; (ii) international markets cannabis; (iii) Storz & Bickel; and (iv) This Works. Information regarding segment net revenue and segment gross margin for the comparative periods has been restated to
reflect the aforementioned change in reportable segments.
8 For Q4 FY2024, amount is net of excise taxes of $8.5 million and other revenue adjustments of $1.0 million (Q4 FY2023 -$9.3 million and $0.6 million, respectively). For FY2024, amount is net of excise taxes of $40.1 million and other revenue adjustments of $3.5 million (FY2023 -$43.1 million and $3.5 million,
respectively).
9 For Q4 FY2024, amount is net of excise taxes of $1.8 million (Q4 FY2023 - $1.3 million). For FY2024, amount is net of excise taxes of $6.7 million (FY2023 - $4.9 million).
10 For Q4 FY2024, amount reflects other revenue adjustments of $0.2 million (Q4 FY2023 - $3.7 million). For FY2024, amount reflects other revenue adjustments of $0.6 million (FY2023 - $8.6 million)
The Company will host a conference call and audio webcast with David Klein, CEO and Judy Hong, CFO at 10:00 AM Eastern Time on May 30, 2024.
Webcast Information
A live audio webcast will be available at https://app.webinar.net/qa1JRpmzw04.
Replay Information
A replay will be accessible by webcast until 11:59 PM Eastern Time on August 28, 2024 at https://app.webinar.net/qa1JRpmzw04.
Adjusted EBITDA is a non-GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Adjusted EBITDA is calculated as the reported net income (loss), adjusted to exclude income tax recovery (expense); other income (expense), net; loss on equity method investments; share-based compensation expense; depreciation and amortization expense; asset impairment and restructuring costs; expected credit losses on financial assets and related charges; restructuring costs recorded in cost of goods sold; and charges related to the flow-through of inventory step-up on business combinations, and further adjusted to remove acquisition-related costs. Asset impairments related to periodic changes to the Company's supply chain processes are not excluded from Adjusted EBITDA given their occurrence through the normal course of core operational activities. The Adjusted EBITDA reconciliation is presented within this news release and explained in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2024 filed with the Securities and Exchange Commission ("SEC").
Free Cash Flow is a non- GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. This measure is calculated as net cash provided by (used in) operating activities less purchases of and deposits on property, plant and equipment. The Free Cash Flow reconciliation is presented within this news release and explained in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2024 filed with the SEC.
Adjusted Gross Margin and Adjusted Gross Margin Percentage are non-GAAP measures used by management that are not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Adjusted Gross Margin is calculated as gross margin excluding restructuring and other charges recorded in cost of goods sold, and charges related to the flow-through of inventory step-up on business combinations. Adjusted Gross Margin Percentage is calculated as Adjusted Gross Margin divided by net revenue. The Adjusted Gross Margin and Adjusted Gross Margin Percentage reconciliation is presented within this news release and explained in the Company's Annual Report on Form 10-K filed for the fiscal year ended March 31, 2024 with the SEC.
Canopy Growth is a world leading cannabis company dedicated to unleashing the power of cannabis to improve lives.
Through an unwavering commitment to our consumers, Canopy Growth delivers innovative products with a focus on premium and mainstream cannabis brands including Doja, 7ACRES, Tweed, and Deep Space. Canopy Growth's CPG portfolio features gourmet wellness products by Martha Stewart CBD, and category defining vaporizer technology made in Germany by Storz & Bickel.
Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through its rights to Acreage Holdings, Inc., ("Acreage") a vertically integrated multi-state cannabis operator with principal operations in densely populated states across the Northeast, as well as Wana Brands, a leading cannabis edible brand in North America, and Jetty Extracts, a California-based producer of high- quality cannabis extracts and pioneer of clean vape technology.
Beyond its world-class products, Canopy Growth is leading the industry forward through a commitment to social equity, responsible use, and community reinvestment - pioneering a future where cannabis is understood and welcomed for its potential to help achieve greater well-being and life enhancement.
For more information visit www.canopygrowth.com.
This press release contains "forward-looking statements" within the meaning of applicable securities laws, which involve certain known and unknown risks and uncertainties. To the extent any forward-looking statements in this news release constitutes "financial outlooks" within the meaning of applicable Canadian securities laws, the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking statements predict or describe our future operations, business plans, business and investment strategies and the performance of our investments. These forward-looking statements are generally identified by their use of such terms and phrases as "intend," "goal," "strategy," "estimate," "expect," "project," "projections," "forecasts," "plans," "seeks," "anticipates," "potential," "proposed," "will," "should," "could," "would," "may," "likely," "designed to," "foreseeable future," "believe," "scheduled" and other similar expressions. Our actual results or outcomes may differ materially from those anticipated. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.
Forward-looking statements include, but are not limited to, statements with respect to:
-- laws and regulations and any amendments thereto applicable to our
business and the impact thereof, including uncertainty regarding the
application of U.S. state and federal law to hemp (including CBD)
products and the scope of any regulations by the U.S. Food and Drug
Administration, the U.S. Drug Enforcement Administration, the U.S.
Federal Trade Commission, the U.S. Patent and Trademark Office, the U.S.
Department of Agriculture (the "USDA") and any state equivalent
regulatory agencies over hemp (including CBD) products;
-- expectations regarding the amount or frequency of impairment losses,
including as a result of the write-down of intangible assets, including
goodwill;
-- our ability to refinance debt as and when required on terms favorable to
us and comply with covenants contained in our debt facilities and debt
instruments;
-- the impacts of the Company's strategy to accelerate entry into the U.S.
cannabis market through the creation of Canopy USA, LLC ("Canopy USA"),
including the costs and benefits associated with the amendments made to
the Canopy USA structure to facilitate the deconsolidation of the
financial results of Canopy USA within the Company's financial
statements;
-- expectations for Canopy USA to capitalize on the opportunity for growth
in the United States cannabis sector and the anticipated benefits of
such strategy;
-- the timing and outcome of the floating share arrangement, whereby,
subject to the terms and conditions of a Floating Share Arrangement
Agreement (the "Floating Share Arrangement Agreement"), Canopy USA is
expected to acquire all of the issued and outstanding Class D
subordinate voting shares (the "Floating Shares") of Acreage by way of a
court-approved plan on arrangement under the Business Corporations Act
(British Columbia) (the "Floating Share Arrangement") in exchange for
0.045 of a Company common share for each Floating Share held, the
anticipated benefits of the Floating Share Arrangement, the anticipated
timing of the acquisition of the Class E subordinate voting shares (the
"Fixed Shares") of Acreage and the Floating Shares by Canopy USA, the
satisfaction or waiver of the closing conditions set out in the Floating
Share Arrangement Agreement and the arrangement agreement dated April
18, 2019, as amended on May 15, 2019, September 23, 2020 and November
17, 2020 (the "Existing Acreage Arrangement Agreement"), including
receipt of all regulatory approvals, and the anticipated timing and
occurrence of the exercise of the option to acquire the Fixed Shares
(the "Acreage Option") and closing of such transaction;
-- the Amended Acreage Arrangement (as defined below) and the Floating
Share Arrangement , including the occurrence or waiver (at the Company's
discretion) of the occurrence or waiver (at the Company's discretion) of
changes in U.S. federal law to permit the general cultivation,
distribution, and possession of marijuana, or to remove the regulation
of such activities from the federal laws of the United States (the
"Triggering Event"), and the satisfaction or waiver of the conditions to
closing the acquisition of Acreage;
-- expectations regarding the option purchased by an affiliate of the
Company for C$38.0 million (US$28.5 million) (the "Option Premium") to
purchase certain of Acreage's debt, including the ability to, and timing
of, the exercise of such option;
-- the transactions contemplated by the our agreement to acquire Wana ,
including the occurrence or waiver (at Canopy USA's discretion) of the
Triggering Event;
-- the issuance of additional common shares of the Company (each whole
share, a "Canopy Share" or a "Share") to satisfy the payments to
eligible participants to the existing tax receivable bonus plans of High
Street Capital Partners, LLC, a subsidiary of Acreage, to satisfy any
deferred and/or option exercise payments to the shareholders of Wana and
Jetty and the issuance of additional non-voting Shares issuable to
Canopy Growth from Canopy USA in consideration thereof;
-- the acquisition of additional Class A shares of Canopy USA in connection
with the investment in Canopy USA by the Huneeus 2017 Irrevocable Trust
(the "Trust") in the aggregate amount of up to US$20 million (the "Trust
Transaction"), including any warrants of Canopy USA issued to the Trust
in accordance with the share purchase agreement entered into by the
Trust and Canopy USA;
-- expectations regarding the laws and regulations and any amendments
thereto relating to the hemp industry in the U.S., including the
promulgation of regulations for the hemp industry by the USDA and
relevant state regulatory authorities;
-- expectations regarding the potential success of, and the costs and
benefits associated with, our acquisitions, joint ventures, strategic
alliances, equity investments and dispositions;
-- the grant, renewal and impact of any license or supplemental license to
conduct activities with cannabis or any amendments thereof;
-- our international activities and joint venture interests, including
required regulatory approvals and licensing, anticipated costs and
timing, and expected impact;
-- our ability to successfully create and launch brands and further create,
launch and scale cannabis-based products and hemp-derived consumer
products in jurisdictions where such products are legal and that we
currently operate in;
-- the benefits, viability, safety, efficacy, dosing and social acceptance
of cannabis, including CBD and other cannabinoids;
-- our ability to maintain effective internal control over financial
reporting;
-- our ability to continue as a going concern;
-- expectations regarding the use of proceeds of equity financings;
-- the legalization of the use of cannabis for medical or adult-use in
jurisdictions outside of Canada, the related timing and impact thereof
and our intentions to participate in such markets, if and when such use
is legalized;
-- our ability to execute on our strategy and the anticipated benefits of
such strategy;
-- the ongoing impact of the legalization of additional cannabis product
types and forms for adult-use in Canada, including federal, provincial,
territorial and municipal regulations pertaining thereto, the related
timing and impact thereof and our intentions to participate in such
markets;
-- the ongoing impact of developing provincial, territorial and municipal
regulations pertaining to the sale and distribution of cannabis, the
related timing and impact thereof, as well as the restrictions on
federally regulated cannabis producers participating in certain retail
markets and our intentions to participate in such markets to the extent
permissible;
-- the timing and nature of legislative changes in the U.S. regarding the
regulation of cannabis including tetrahydrocannabinol ;
-- the future performance of our business and operations;
-- our competitive advantages and business strategies;
-- the competitive conditions of the industry;
-- the expected growth in the number of customers using our products;
-- our ability or plans to identify, develop, commercialize or expand our
technology and research and development initiatives in cannabinoids, or
the success thereof;
-- expectations regarding revenues, expenses and anticipated cash needs;
-- expectations regarding cash flow, liquidity and sources of funding;
-- expectations regarding capital expenditures;
-- the expansion of our production and manufacturing, the costs and timing
associated therewith and the receipt of applicable production and sale
licenses;
-- expectations with respect to our growing, production and supply chain
capacities;
-- expectations regarding the resolution of litigation and other legal and
regulatory proceedings, reviews and investigations;
-- expectations with respect to future production costs;
-- expectations with respect to future sales and distribution channels and
networks;
-- the expected methods to be used to distribute and sell our products;
-- our future product offerings;
-- the anticipated future gross margins of our operations;
-- accounting standards and estimates;
-- expectations regarding our distribution network;
-- expectations regarding the costs and benefits associated with our
contracts and agreements with third parties, including under our
third-party supply and manufacturing agreements;
-- our ability to comply with the listing requirements of the Nasdaq Stock
Market LLC and the Toronto Stock Exchange ; and
-- expectations on price changes in cannabis markets.
Certain of the forward-looking statements contained herein concerning the industries in which we conduct our business are based on estimates prepared by us using data from publicly available governmental sources, market research, industry analysis and on assumptions based on data and knowledge of these industries, which we believe to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. The industries in which we conduct our business involve risks and uncertainties that are subject to change based on various factors, which are described further below.
The forward-looking statements contained herein are based upon certain material assumptions , including: (i) management's perceptions of historical trends, current conditions and expected future developments; (ii) our ability to generate cash flow from operations; (iii) general economic, financial market, regulatory and political conditions in which we operate; (iv) the production and manufacturing capabilities and output from our facilities and our joint ventures, strategic alliances and equity investments; (v) consumer interest in our products; (vi) competition; (vii) anticipated and unanticipated costs; (viii) government regulation of our activities and products including but not limited to the areas of taxation and environmental protection; (ix) the timely receipt of any required regulatory authorizations, approvals, consents, permits and/or licenses; (x) our ability to obtain qualified staff, equipment and services in a timely and cost-efficient manner; (xi) our ability to conduct operations in a safe, efficient and effective manner; (xii) our ability to realize anticipated benefits, synergies or generate revenue, profits or value from our recent acquisitions into our existing operations; and (xiii) other considerations that management believes to be appropriate in the circumstances. While our management considers these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. Financial outlooks, as with forward-looking statements generally, are, without limitation, based on the assumptions and subject to various risks as set out herein. Our actual financial position and results of operations may differ materially from management's current expectations.
By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking statements in this press release and other reports we file with, or furnish to, the SEC and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf. Such factors include, without limitation, our limited operating history; our ability to continue as a going concern; risks that we may be required to write down intangible assets, including goodwill, due to impairment; the adequacy of our capital resources and liquidity, including but not limited to, availability of sufficient cash flow to execute our business plan (either within the expected timeframe or at all); our ability to maintain an effective system of internal control; the diversion of management time on matters related to Canopy USA; the ability of parties to certain transactions to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholder approvals; the risks that the Trust's future ownership interest in Canopy USA is not quantifiable, and the Trust may have significant ownership and influence over Canopy USA; the risks relating to the conditions set forth in the Floating Share Arrangement Agreement and the Existing Acreage Arrangement Agreement not being satisfied or waived; the risks related to Acreage's financial statements expressing doubt about its ability to continue as a going concern; the risks related to the Company losing the Option Premium; the risks in the event that Acreage cannot satisfy its debt obligations as they become due; the risks related to the fact that the Company has not received audited financial statements with respect to Jetty; volatility in and/or degradation of general economic, market, industry or business conditions; risks relating to our current and future operations in emerging markets; compliance with applicable environmental, economic, health and safety, energy and other policies and regulations and in particular health concerns with respect to vaping and the use of cannabis and hemp products in vaping devices; risks and uncertainty regarding future product development; changes in regulatory requirements in relation to our business and products; our reliance on licenses issued by and contractual arrangements with various federal, state and provincial governmental authorities; inherent uncertainty associated with projections; future levels of revenues and the impact of increasing levels of competition; third-party manufacturing risks; third-party transportation risks; inflation risks; our exposure to risks related to an agricultural business, including wholesale price volatility and variable product quality; changes in laws, regulations and guidelines and our compliance with such laws, regulations and guidelines; risks relating to inventory write downs; risks relating to our ability to refinance debt as and when required on terms favorable to us and to comply with covenants contained in our debt facilities and debt instruments; risks associated with jointly owned investments; our ability to manage disruptions in credit markets or changes to our credit ratings; the success or timing of completion of ongoing or anticipated capital or maintenance projects; risks related to the integration of acquired businesses; the timing and manner of the legalization of cannabis in the United States; business strategies, growth opportunities and expected investment; counterparty risks and liquidity risks that may impact our ability to obtain loans and other credit facilities on favorable terms; the potential effects of judicial, regulatory or other proceedings, litigation or threatened litigation or proceedings, or reviews or investigations, on our business, financial condition, results of operations and cash flows; risks associated with divestment and restructuring; the anticipated effects of actions of third parties such as competitors, activist investors or federal, state, provincial, territorial or local regulatory authorities, self-regulatory organizations, plaintiffs in litigation or persons threatening litigation; consumer demand for cannabis and hemp products; the implementation and effectiveness of key personnel changes; risks related to stock exchange restrictions; risks related to the protection and enforcement of our intellectual property rights; the risks related to the Exchangeable Shares having different rights from Canopy Shares and there may never be a trading market for the Exchangeable Shares; future levels of capital, environmental or maintenance expenditures, general and administrative and other expenses; and the factors discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2024. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements.
Forward-looking statements are provided for the purposes of assisting the reader in understanding our financial performance, financial position and cash flows as of and for periods ended on certain dates and to present information about management's current expectations and plans relating to the future, and the reader is cautioned that the forward-looking statements may not be appropriate for any other purpose. While we believe that the assumptions and expectations reflected in the forward-looking statements are reasonable based on information currently available to management, there is no assurance that such assumptions and expectations will prove to have been correct. Forward-looking statements are made as of the date they are made and are based on the beliefs, estimates, expectations and opinions of management on that date. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking statements, except as required by law. The forward-looking statements contained in this press release and other reports we file with, or furnish to, the SEC and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf are expressly qualified in their entirety by these cautionary statements.
Error occurred while generating ASCII Content for table
(1)
Prior year share amounts have been retrospectively adjusted to reflect the Share Consolidation (as defined in the FY2024 Form 10-K), which became effective on December 15, 2023.
CANOPY GROWTH CORPORATION
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands of Canadian dollars, except number of shares and per share data, unaudited)
Three months ended March 31, Years ended March 31,
2024 2023 2024 2023
Revenue $
83,153 $
78,853 $
343,934 $
381,250
Excise taxes 10,365 10,618 46,788 47,997
Net revenue 72,788 68,235 297,146 333,253
Cost of goods sold 57,320 132,556 216,264 396,782
Gross margin 15,468 (64,321) 80,882 (63,529)
Operating expenses
Selling, general and administrative expenses 54,619 71,092 229,429 342,517
Share-based compensation 4,053 4,429 14,180 25,322
Loss on asset impairment and restructuring 63,535 404,934 65,987 2,199,146
Total operating expenses 122,207 480,455 309,596 2,566,985
Operating loss from continuing operations (106,739) (544,776) (228,714) (2,630,514)
Other income (expense), net 10,629 (59,570) (242,641) (455,644)
Loss from continuing operations before income taxes (96,110) (604,346) (471,355) (3,086,158)
Income tax (expense) recovery 1,435 16,361 (12,327) 5,728
Net loss from continuing operations (94,675) (587,985) (483,682) (3,080,430)
Net income (loss) from discontinued operations, net of 2,338 (59,624) (192,113) (229,116)
income tax
Net loss (92,337) (647,609) (675,795) (3,309,546)
Net loss from continuing operations attributable to (561) (1,897)
noncontrolling interests and redeemable
noncontrolling interest
Net loss from discontinued operations attributable to (6,968) (18,526) (29,491)
noncontrolling interests and redeemable
noncontrolling interest
Net loss attributable to Canopy Growth Corporation $
(92,337) $
(640,080) $
(657,269) $
(3,278,158)
Basic and diluted loss per share(1)
Continuing operations $
(1.06) $
(11.78) $
(6.47) $
(66.39)
Discontinued operations 0.03 (1.05) (2.32) (4.30)
Basic and diluted loss per share $
(1.03) $
(12.83) $
(8.79) $
(70.69)
Basic and diluted weighted average common shares 89,500,859 49,877,806 74,787,521 46,372,441
outstanding(1)
(1)
Prior year share amounts have been retrospectively adjusted to reflect the Share Consolidation (as defined in the FY2024 Form 10-K), which became effective on December 15, 2023.
Schedule 3
CANOPY GROWTH CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands of Canadian dollars, unaudited)
Years ended March 31,
2024 2023
Cash flows from operating activities:
Net loss $
(675,795) $
(3,309,546)
Loss from discontinued operations, net of income tax (192,113) (229,116)
Net loss from continuing operations (483,682) (3,080,430)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant and equipment 28,376 55,575
Amortization of intangible assets 24,800 24,458
Share-based compensation 14,180 25,322
Loss on asset impairment and restructuring 53,797 2,170,588
Income tax expense (recovery) 12,327 (5,728)
Non-cash fair value adjustments and charges related to 160,468 353,827
settlement of unsecured senior notes
Change in operating assets and liabilities, net of effects from
purchases of businesses:
Amounts receivable (3,749) 6,242
Inventory 1,034 68,438
Prepaid expenses and other assets (2,433) 12,530
Accounts payable and other accrued expenses and accrued liabilities 9,115 (28,240)
Other, including non-cash foreign currency (42,654) 2,995
Net cash used in operating activities - continuing operations (228,421) (394,423)
Net cash used in operating activities - discontinued operations (53,529) (163,123)
Net cash used in operating activities (281,950) (557,546)
Cash flows from investing activities:
Purchases of and deposits on property, plant and equipment (3,449) (9,114)
Purchases of intangible assets (547) (1,337)
Proceeds on sale of property, plant and equipment 154,052 13,609
Redemption of short-term investments 78,549 502,589
Net cash (outflow) proceeds on sale of subsidiaries (955) 14,932
Investment in other financial assets (347) (67,150)
Other investing activities (7,705) 3,900
Net cash provided by investing activities - continuing operations 219,598 457,429
Net cash provided by (used in) investing activities - discontinued operations 21,992 (24,050)
Net cash provided by investing activities 241,590 433,379
Cash flows from financing activities:
Proceeds from issuance of common shares and warrants 81,063 1,049
Proceeds from exercise of stock options 281
Issuance of long-term debt and convertible debentures 135,160
Repayment of long-term debt (509,779) (118,179)
Other financing activities (36,339) (38,005)
Net cash used in financing activities (465,055) (19,694)
Effect of exchange rate changes on cash and cash equivalents (1,292) 44,863
Net decrease in cash and cash equivalents (506,707) (98,998)
Cash and cash equivalents, beginning of period(1) 677,007 776,005
Cash and cash equivalents, end of period(2) $
170,300 $
677,007
(1)
Includes cash of our discontinued operations of $9,314, and $13,610 for March 31, 2023 and 2022, respectively.
(2)
Includes cash of our discontinued operations of $nil and $9,314 for March 31, 2024 and 2023, respectively.
Adjusted Gross Margin(1) Reconciliation (Non-GAAP Measure)
Three months ended March 31,
(in thousands of Canadian dollars except where indicated; unaudited) 2024 2023
Net revenue $
72,788 $
68,235
Gross margin, as reported 15,468 (64,321)
Adjustments to gross margin:
Restructuring costs recorded in cost of goods sold (297) 71,673
Adjusted gross margin(1) $
15,171 $
7,352
Adjusted gross margin percentage(1) 21 11
% %
(1)
Adjusted gross margin and adjusted gross margin percentage are non-GAAP measures. See "Non-GAAP Measures".
Years ended March 31,
(in thousands of Canadian dollars except where indicated; unaudited) 2024 2023
Net revenue $
297,146 $
333,253
Gross margin, as reported 80,882 (63,529)
Adjustments to gross margin:
Restructuring costs recorded in cost of goods sold (986) 81,802
Adjusted gross margin(1) $
79,896 $
18,273
Adjusted gross margin percentage(1) 27 5
% %
(1)
Adjusted gross margin and adjusted gross margin percentage are non-GAAP measures. See "Non-GAAP Measures".
Adjusted EBITDA
(1)
Reconciliation (Non-GAAP
Measure)
Three months ended March
31,
(in thousands of Canadian dollars, unaudited) 2024 2023
Net loss from continuing operations $
(94,675) $
(587,985)
Income tax recovery (1,435) (16,361)
Other (income) expense, net (10,629) 59,570
Share-based compensation 4,053 4,429
Acquisition, divestiture, and other costs 13,062 4,038
Depreciation and amortization(2) 11,295 19,301
Loss on asset impairment and restructuring 63,535 404,934
Restructuring costs recorded in cost of goods sold (297) 71,673
Adjusted EBITDA(1) $
(15,091) $
(40,401)
(1)
Adjusted EBITDA is a non-GAAP measure. See "Non-GAAP Measures".
2
From Consolidated Statements of Cash Flows.
Years ended March 31,
(in thousands of Canadian dollars, unaudited) 2024 2023
Net loss from continuing operations $
(483,682) $
(3,080,430)
Income tax expense (recovery) 12,327 (5,728)
Other (income) expense, net 242,641 455,644
Share-based compensation 14,180 25,322
Acquisition, divestiture, and other costs 37,435 35,584
Depreciation and amortization(2) 53,176 80,033
Loss on asset impairment and restructuring 65,987 2,199,146
Restructuring costs recorded in cost of goods sold (986) 81,802
Adjusted EBITDA(1) $
(58,922) $
(208,627)
(1)
Adjusted EBITDA is a non-GAAP measure. See "Non-GAAP Measures".
2
From Consolidated Statements of Cash Flows.
Free Cash Flow(1) Reconciliation (Non-GAAP Measure)
Three months ended March
31,
(in thousands of Canadian dollars, unaudited) 2024 2023
Net cash used in operating activities - continuing operations (22,460) (95,633)
Purchases of and deposits on property, plant and equipment (249) (2,938)
- continuing operations
Free cash flow - continuing operations(1) (22,709) (98,571)
(1)
Free cash flow is a non-GAAP measure. See "Non-GAAP Measures".
Years ended March 31,
(in thousands of Canadian dollars, unaudited) 2024 2023
Net cash used in operating activities - continuing operations (228,421) (394,423)
Purchases of and deposits on property, plant and equipment (3,449) (9,114)
- continuing operations
Free cash flow - continuing operations(1) (231,870) (403,537)
(1)
Free cash flow is a non-GAAP measure. See "Non-GAAP Measures".
Segmented Gross Margin and Segmented Adjusted Gross Margin(1) Reconciliation (Non-GAAP Measure)
Three months ended March 31,
(in thousands of Canadian dollars except where indicated; unaudited) 2024 2023
Canada cannabis segment
Net revenue $
37,082 $
35,731
Gross margin, as reported 157 (69,826)
Gross margin percentage, as reported 0 (195)
% %
Adjustments to gross margin:
Restructuring costs recorded in cost of goods sold 69,589
Adjusted gross margin(1) $
157 $
(237)
Adjusted gross margin percentage(1) 0 (1)
% %
International markets cannabis segment
Revenue $
11,646 $
8,770
Gross margin, as reported 6,318 354
Gross margin percentage, as reported 54 4
% %
Adjustments to gross margin:
Restructuring costs recorded in cost of goods sold (297) 938
Adjusted gross margin(1) $
6,021 $
1,292
Adjusted gross margin percentage(1) 52 15
% %
Storz & Bickel segment
Revenue $
22,153 $
15,494
Gross margin, as reported 9,054 5,303
Gross margin percentage, as reported 41 34
% %
Adjusted gross margin(1) $
9,054 $
5,303
Adjusted gross margin percentage(1) 41 34
% %
This Works segment
Revenue
$ $
5,352
Gross margin, as reported 1,223
Gross margin percentage, as reported 0 23
% %
Adjustments to gross margin:
Restructuring costs recorded in cost of goods sold 1,146
Adjusted gross margin(1)
$ $
2,369
Adjusted gross margin percentage(1) 0 44
% %
Other
Revenue $
1,907 $
2,888
Gross margin, as reported (61) (1,375)
Gross margin percentage, as reported (3) (48)
% %
Adjusted gross margin(1) $
(61) $
(1,375)
Adjusted gross margin percentage(1) (3) (48)
% %
(1)
Adjusted gross margin and adjusted gross margin percentage are non-GAAP measures. See "Non-GAAP Measures".
Years ended March 31,
(in thousands of Canadian dollars except where indicated; unaudited) 2024 2023
Canada cannabis segment
Net revenue $
153,716 $
187,067
Gross margin, as reported 24,896 (95,291)
Gross margin percentage, as reported 16 (51)
% %
Adjustments to gross margin:
Restructuring costs recorded in cost of goods sold (689) 71,278
Adjusted gross margin(1) $
24,207 $
(24,013)
Adjusted gross margin percentage(1) 16 (13)
% %
International markets cannabis segment
Revenue $
41,312 $
38,949
Gross margin, as reported 16,682 (3,322)
Gross margin percentage, as reported 40 (9)
% %
Adjustments to gross margin:
Restructuring costs recorded in cost of goods sold (297) 8,224
Adjusted gross margin(1) 16,385 4,902
Adjusted gross margin percentage(1) 40 13
% %
Storz & Bickel segment
Revenue $
70,670 $
64,845
Gross margin, as reported 30,128 26,112
Gross margin percentage, as reported 43 40
% %
Adjusted gross margin(1) 30,128 26,112
Adjusted gross margin percentage(1) 43 40
% %
This Works segment
Revenue $
21,256 $
26,029
Gross margin, as reported 10,534 10,205
Gross margin percentage, as reported 50 39
% %
Adjustments to gross margin:
Restructuring costs recorded in cost of goods sold 2,300
Adjusted gross margin(1) $
10,534 $
12,505
Adjusted gross margin percentage(1) 50 48
% %
Other
Revenue $
10,192 $
16,363
Gross margin, as reported (1,358) (1,233)
Gross margin percentage, as reported (13) (8)
% %
Adjusted gross margin(1) $
(1,358) $
(1,233)
Adjusted gross margin percentage(1) (13) (8)
% %
(1)
Adjusted gross margin and adjusted gross margin percentage are non-GAAP measures. See "Non-GAAP Measures".
View original content to download multimedia:https://www.prnewswire.com/news-releases/canopy-growth-reports-fourth-quarter-and-fiscal-year-2024-financial-results-q4-fy2024-net-revenue-increased-7-year-over-year-or-16-excluding-divested-businesses-302158907.html
SOURCE Canopy Growth Corporation
